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A recurrent de novo heterozygous COG4 variant leads to Saul-Wilson syndrome, disruption of 
vesicular trafficking, abnormal Golgi structure and altered glycosylation of a secreted 
proteoglycan 
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Abstract 
The conserved oligomeric Golgi (COG) complex is involved in intracellular vesicular transport, 
and is composed of eight subunits distributed in two lobes, lobe A (COG1-4) and lobe B (COG5-
8). We describe fourteen individuals with Saul-Wilson syndrome, a rare form of primordial 
dwarfism with characteristic facial and radiographic features. All affected subjects harbored 
heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid 
substitution (p.Gly516Arg). Affected individuals’ fibroblasts, whose COG4 mRNA and protein 
were not decreased, exhibited delayed anterograde vesicular trafficking from the ER to the 
Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER. This altered 
steady-state equilibrium led to a decrease in Golgi volume, as well as morphologic 
abnormalities with collapse of the Golgi stacks. Despite these abnormalities of the Golgi 
apparatus, protein glycosylation in sera and fibroblasts from affected subjects was not notably 
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altered, but decorin, a proteoglycan secreted into the extracellular matrix, showed altered 
Golgi-dependent glycosylation. In summary, we define a specific heterozygous COG4 variant as 
the molecular basis of Saul-Wilson syndrome, a rare skeletal dysplasia distinct from biallelic 
COG4-CDG. 
 
Introduction 
Saul-Wilson syndrome (SWS) is a rare skeletal dysplasia with characteristic dysmorphic and 
radiographic findings, as well as early developmental delay, primarily involving speech, with 
eventual normal cognition. Clinical findings include marked short stature, prominent forehead 
with an enlarged anterior fontanel, prominent eyes with cataracts, narrow nasal bridge with a 
convex nasal ridge, micrognathia, clubfoot, brachydactyly, and short distal phalanges of fingers. 
Radiographic changes include platyspondyly, irregular end plates of vertebral bodies, and 
hypoplasia of the odontoid process with cervical instability in the spine, coxa valga, 
overtubulation, metaphyseal flaring and megaepiphyses in the long bones, while the hands and 
feet exhibit short phalanges, metacarpals and metatarsals, cone-shaped epiphyses of 
phalanges, and accessory ossification centers of metacarpals and metatarsals. Since its original 
description in 1990 as a provisionally new skeletal dysplasia, only five cases have been 
reported,1–3 all from different families. Some essential characteristics of SWS (i.e. severe pre-
and postnatal growth retardation with possible microcephaly and skeletal dysplasia) can fall 
within the category of microcephalic osteodysplastic primordial dwarfism.4,5 In fact, a prior 
nosology of genetic skeletal disorders included SWS in the same group of slender bone 
dysplasias that contained microcephalic osteodysplastic primordial dwarfism type II (MOPDII, 
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OMIM 210720).6 However, due to the uncertainty about the etiology and identity of SWS as a 
genetic disorder, it was excluded from the two subsequent nosologies7,8 and, due to its rarity, it 
is not included as a discrete entity in the Online Mendelian Inheritance in Man (OMIM) catalog.  
 
Here we present fourteen individuals with SWS and a recurrent de novo heterozygous variant in 
COG4 (MIM: 606976, NM_015386.2:c.1546G>A or c.1546G>C/p.Gly516Arg), a component of 
the Complex Oligomeric Golgi (COG) trafficking complex. The COG complex controls retrograde 
and anterograde vesicular protein trafficking and is composed of eight subunits distributed in 
two lobes, lobe A (COG1-4) and lobe B (COG5-8).9 The COG complex interacts with various 
other proteins involved in vesicular trafficking, including SNARES, SNARE-interacting proteins, 
Rab GTPases, coiled-coil tethers, and COPI coat proteins.10 Our description of the basic 
molecular defect in SWS expands the phenotypic spectrum of the disease and helps elucidate 
the cellular pathogenesis of this rare skeletal dysplasia.  
 
Materials and methods 
Subjects  
Individual P1.1 was initially seen at Vanderbilt Children’s Hospital and enrolled under protocol 
15-HG-0130, “Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders 
Through the Undiagnosed Diseases Network”.11–13 Upon further clinical analysis at the National 
Institutes of Health Clinical Center this subject was enrolled in protocol 14-HG-0071 “Clinical 
and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation”. 
Individuals P2.1 and P7.1 were also enrolled in protocol 14-HG-0071. Individuals P3.1, P4.1, 
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P5.1, P6.1, P9.1, P10.1, P11.1, P12.1 and P13.1 were enrolled in protocol 76-HG-0238, 
“Diagnosis and Treatment of Patients with Inborn Errors of Metabolism or Other Genetic 
Disorders”. The aforementioned protocols were approved by the National Human Genome 
Research Institute (NHGRI) Institutional Review Board (IRB). 
 
Individuals P3.1, P4.1 and P8.1 were enrolled in research protocol “Enquiry of participation in a 
research project about clinical and molecular studies on rare congenital skeletal disorders”, 
approved by the IRB of the Karolinska Institute in Sweden (2014/983-31/1). Individuals P2.1, 
P5.1, P5.2 and P7.1 were enrolled in the Primordial Registry at Nemours/Alfred I. duPont 
Hospital for Children, approved by the Nemours IRB, and sequencing of individuals P2.1 and 
P7.1 was approved by the Scottish Multicentre Research Ethics Committee (04:MRE00/19). 
Individuals P5.1, P5.2, P6.1, P9.1, P10.1, P11.1 and P12.1 underwent sequencing on a clinical 
basis. Written consent was obtained from all affected individuals or their parents. 
 
Fibroblast cultures 
From a forearm skin punch biopsy, primary dermal fibroblasts were cultured from individuals 
P1.1, P2.1, P3.1, P4.1, P5.1, P7.1, P9.1 and P12.1; age- and gender-matched control cell lines 
were obtained from Coriell Institute for Medical Research (Camden, NJ, USA) and American 
Type Culture Collection (ATCC, Manassas, VA, USA). Fibroblasts were cultured in Dulbecco's 
Modified Eagle's medium (DMEM) containing 1 g/L glucose (4.5 g/L for mRNA expression, co-
immunoprecipitation and Golgi morphology experiments) supplemented with 10% heat 
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inactivated fetal bovine serum and 1% antibiotic-antimycotic (Life Technologies, Carlsbad, CA, 
USA).  
 
Genetic analysis 
Different technologies and analysis pipelines were used for subjects sequenced by seven 
different institutions; details are presented in the Supplemental Methods section.  
 
mRNA expression analysis 
Total RNA was extracted from frozen fibroblast pellets using a Maxwell RSC instrument with the 
corresponding simplyRNA Cells Kit (Promega, Madison, WI, USA) following the manufacturers 
protocol with DNase1 treatment. Two g of RNA was reverse transcribed using the Omniscript 
Reverse Transcriptase kit (Qiagen, Valencia, CA, USA). Quantitative RT-PCR was performed on 
an Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies, Grand Island, NY, 
USA) using a TaqMan gene-expression mastermix and the following TaqMan assays: COG1 
(Hs00372622_m1), COG2 (Hs00201197_m1), COG3 (Hs00230134_m1), COG4 
(Hs01094456_m1), COG5 (Hs00197140_m1), COG6 (Hs01037401_m1), COG7 
(Hs00411394_m1) and COG8 (Hs00260744_m1). Expression was normalized using GAPDH 
(Hs02758991_g1) and POLR2A (Hs00172187_m1) as endogenous controls.   
 
Protein level analysis 
For analysis of COG4, cells were harvested using SDS lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% 
SDS, and 10% glycerol) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, 
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St. Louis, MO, USA). Lysates were sonicated, heated at 95°C for 5 min followed by 
centrifugation at 10,000 rpm for 5 min. Equivalent amounts of total lysates were then 
fractionated on a 4-15% polyacrylamide gel and transferred to a nitrocellulose membrane using 
the Transblot Turbo transfer system (Bio-Rad, Hercules, CA, USA). The membrane was blocked 
with Odyssey TBS Blocking buffer (LI-COR, Lincoln, NE, USA) and probed with anti-COG4 
antibody produced in rabbit (A305-555A, Bethyl Laboratories, Montgomery, TX, USA) and anti-
Vinculin antibody produced in mouse (V9131, Sigma Aldrich, St. Louis, MO, USA). Secondary 
antibodies Donkey anti-rabbit IRDye 680RD and Donkey anti-mouse IRDye 800CW (LI-COR, 
Lincoln, NE, USA) were applied and imaging was done using a 9140 Odyssey CLx infrared 
imaging system with Image Studio software for analysis (LI-COR, Lincoln, NE, USA). 
 
For analysis of other COG subunits, human fibroblast cells were harvested by SDS lysis buffer as 
previously described.14 The lysates (10 µg of protein) obtained from each cell line were 
fractionated by SDS-PAGE on 8% gels and immunoblotted with rabbit polyclonal COG subunit 
antibodies (COG antibodies provided by Dr. Daniel Ungar, University of York, UK). The blots 
were developed using a SuperSignal West Dura enhanced chemiluminescence kit 
(ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions, and 
quantified by ImageJ (National Institutes of Health, Bethesda, MD, USA). 
 
Protein modeling 
The rope structure of three-dimensional protein homology models of wild-type and mutant 
(p.Gly516Arg) COG4 were built using the web interface of SWISS-MODEL with its default 
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settings.15,16 Amino acid sequence of conserved oligomeric Golgi complex subunit 4 isoform 1 
(NP_056201.2) in FASTA format was used as input. Template search was performed 
automatically by SWISS-MODEL using BLAST17 and HHblits.18 The template's quality was 
predicted from features of the target-template alignment, and the templates with the highest 
quality were selected for model building. The models were built based on the target-template 
alignment using ProMod3. The global and per-residue model quality was assessed using the 
QMEAN scoring function.19  
 
The modeled COG4 protein (aa range between 202-787) was superimposed onto the structural 
template 3HR0 (aa range between 540-789) to further evaluate the similarity of the modeled 
protein to the X-ray crystal of the C-terminal COG4 protein.20 
 
Co-immunoprecipitation 
Fibroblasts from control and three affected subjects were lysed in ice-cold Triton X-100 lysis 
buffer (50 mM Tris, pH 7.5, 150 mM sodium chloride, 1mM EDTA, 0.5% Triton X-100) 
supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). 
Cell lysates were centrifuged at 10,000 rpm (9,279g) for 10 min at 4°C to remove insoluble 
material. Subsequently, equivalent amounts of protein extracts were incubated with rabbit 
polyclonal anti-COG4 antibody (Bethyl Laboratories, Montgomery, TX, USA) for 2 h at 4°C and 
then with protein A beads overnight. After incubation, immunoprecipitates were washed three 
times with lysis buffer without protease or phosphatase inhibitors, eluted in SDS sample 
 10 
buffer and separated by SDS-PAGE. The different COG subunits were detected by 
immunoblotting using the indicated antibodies (Bethyl Laboratories, Montgomery, TX, USA).  
 
Golgi morphology by immunofluorescence 
For analysis of Golgi morphology, fibroblasts were seeded at 0.5 x 105 per 12-mm round 
coverslip. After an overnight incubation at 37°C, the cells were fixed with 4% paraformaldehyde 
in PBS and permeabilized with 0.5% NP-40 in PBS. Coverslips were incubated for 1 h with 4% 
bovine serum albumin (BSA) in PBS and probed with anti-GM130 produced in mouse (BD 
Biosciences, Franklin Lakes, NJ, USA) and anti-TGN46 produced in sheep (Genetex, Irvine, CA, 
USA) overnight at 4°C. After washing in PBS, they were incubated for 1 h with secondary Alexa 
Fluor-555 donkey anti-mouse IgG and Alexa Fluor-488 donkey anti-sheep IgG (Life 
Technologies, Grand Island, NY, USA), co-stained with Hoescht 33342 and mounted using 
ProLong Gold Antifade Mountant (Life Technologies, Carlsbad, CA, USA). Z-stacked images were 
obtained using a Zeiss LSM700 confocal laser-scanning microscope with a 63x oil-based 
objective and a 20x objective and Images were processed with LSM software ZEN Black 2012 
software (Carl Zeiss Microscopy GmbH, Jena, Germany).  
 
Golgi three-dimensional rendering and volumetric analysis 
Alexa Fluor 488 anti-Giantin antibodies (BioLegend, San Diego, CA, USA) were used as a marker 
of the Golgi. All fibroblast Z-series reconstructions were imaged with a pinhole size of 1 Airy 
Unit and a Z-step interval of 0.2 µm at 4x magnification. LSM Z-series files of the Golgi were 
opened in Imaris software (Bitplane, South Windsor, CT, USA) as volumes, and the surface of 
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the Golgi was smoothened by setting the surface detail at 0.1 µm. Each Golgi isosurface was 
visually inspected to ensure that it closely followed the underlying original three-dimensional 
image and did not incorporate voxels outside of the observable Golgi region. Each isosurfaced 
Golgi was selected and its volume recorded.21 The nucleus was stained with DAPI (GeneTex Inc., 
Alton Pkwy, Irvine, CA) and its volume measured as above; the surface detail was set at 1 µm. 
 
Decorin immunoblotting 
For secreted decorin analysis, fibroblast cells were grown in normal condition for three days to 
reach ~80% confluency, then the media was replaced with serum-free medium. After 4 days, 
the medium was collected and concentrated using Microcon centrifugal filter unit YM-10 
columns (MilliporeSigma, Darmstadt, Germany). For intracellular decorin analysis, cells were 
lysed in 0.1M Tris-Cl pH 8.0 buffer with protease inhibitor cocktail (Roche, Mannheim, 
Germany) followed by sonication. The concentrated media and cell lysate from fibroblast 
cultures were subjected to SDS–PAGE using 6 or 8% SDS polyacrylamide gels. Separated 
proteins were transferred to a PVDF membrane and decorin was detected with anti-human 
decorin antibody (clone 115402; R&D Systems, Minneapolis, MN, USA).  
 
Brefeldin A-induced transport assays 
For the brefeldin A (BFA)-induced retrograde transport assay, fibroblasts from two controls and 
four subjects were grown on glass cover slips for two days. After removal of the medium, cells 
were incubated with prewarmed normal growth medium containing 0.25 µg/ml BFA for 0, 7.5, 
15, 22.5, 30 and 45 min at 23ᵒC. The incubations were stopped by washing cells with DPBS and 
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cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were 
permeabilized and stained by immunofluorescence using Alexa Fluor 488 anti-Giantin 
antibodies (BioLegend, San Diego, CA, USA). The percentage of cells with ER staining was 
determined at the given time points. Images were obtained using an Olympus IX71 microscope 
(Olympus Corporation, Tokyo, Japan), and processed by MetaMorph software (Molecular 
Devices, San Jose, CA, USA). Between 80 to 100 cells were counted in replicate samples for each 
time point. A similar assay was performed using TGN46 (a marker of the trans-Golgi network) 
instead of Giantin (a cis- and medial-Golgi marker) antibodies. Primary antibody was anti-
TGN46 produced in sheep (Genetex, Irvine, CA, USA) while secondary antibodies were Alexa 
Fluor-488 donkey anti-sheep IgG (Life Technologies, Grand Island, NY, USA). 
For the anterograde transport assay, fibroblasts from two unaffected controls, four subjects 
and a positive control obtained from an individual with biallelic variants in COG822 were grown 
on glass cover slips for two days. After incubating the cells with 0.25 µg/ml brefeldin A for 1 h at 
37ᵒC, cells were washed with DPBS twice, then switched to new plates with prewarmed normal 
growth medium and incubated for 0, 20, 30, 40, 60, 80, 100 and 120 min at 37ᵒC. The 
incubations were stopped and processed as described above. 
 
COG complex subcellular fractionation  
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Fibroblasts from a control and an affected individual were gently collected by cell lifter, 
followed by cell disruption and differential centrifugation as previously described,23 in order to 
assess the distribution of the COG subunits in their cytosolic and membrane-bound fractions.  
 
Assessment of COG complex assembly by glycerol gradient centrifugation 
Preparation of cytosolic and membrane-bound fractions for density centrifugation of one 
control and one subject fibroblast cell lines was performed as described24 with slight 
modification. Briefly, samples were prepared and concentrated by Microcon centrifugal filter 
unit YM-30 columns (MilliporeSigma, Darmstadt, Germany) and loaded onto a 12 ml 10-30% 
glycerol (w/v) gradient. The gradients were centrifuged in a Beckman SW40 rotor at 120,000g 
for 24 h. Fractions of 1 ml were collected via a hole punched at the bottom of the tubes. The 
glycerol concentrations of the 12 fractions from each gradient collection were determined by 
testing the refractive index with a refractometer (REED instruments, Wilmington, NC, USA) and 
thyroglobulin (molecular weight 669 Kda) was used as an internal marker in each run. 
Trichloroacetic acid precipitation was performed followed by Western blot assays in order to 
measure the protein concentration of the samples. 
 
Zebrafish maintenance and staging 
Wild-type ABCxTu, cog4b1311, cog4b1312 and transgenic Tg[p7.2sox10:mRFP]vu234 adult zebrafish25 
were maintained as previously described.26 Embryos and larvae were staged according to the 
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standard staging series.27 All zebrafish procedures were approved by the University of Oregon 
Institutional Animal Care and Use Committee (IACUC). 
 
Zebrafish immunolabeling, in situ hybridization, phalloidin staining and Alcian blue staining  
Wholemount larvae were labeled following previously published protocols28 with minor 
modifications. Five dpf larvae were fixed in BT fixative overnight and permeabilized in 2.5% 
Tween-20 for 18 h. Primary antibodies were rabbit anti-Cog4 (Novus Biologicals, Littleton, CO, 
USA; 1:500), mouse anti-Collagen type II (Developmental Studies Hybridoma Bank, Iowa City, 
IA, USA; II-II6B3, 1:200), and mouse anti-GM130 (BD Transduction Laboratories, 1:500). 
Secondary antibodies were biotinylated horse anti-rabbit and biotinylated horse anti-mouse 
(Vector Laboratories, Burlingame, CA, USA; 1:500). The procedure for the in situ hybridization 
followed previously published protocols.28 Larvae were hybridized with a digoxigenin-labeled 
RNA probe spanning a 736 bp coding sequence between exons 3 and 8 of cog4. Stained larvae 
were embedded in 1% agarose, 0.5% agar, 5% sucrose medium, and 16 µm cryosections were 
cut. Zebrafish RNA probe for collagen I alpha2 (col1a2) was kindly provided by Dr. John H. 
Postlethwait. Phalloidin staining was performed as previously described.29 Alcian blue staining 
was performed as previously described.30 
 
Generation of indel mutant alleles using CRISPR 
Two single guide RNAs (sgRNA) were designed that contained targeting sequences in exon 4 (5’-
GGCTGTACCAAGCGATTCAG-3’) and exon 12 (5’-GCTCTGCAGGACCTGCAGCG-3’) of cog4, 
respectively. sgRNA and cas9 RNAs were co-injected at the 1-cell stage. Indel mutations were 
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identified using the following primers: targeted sequence in exon 4: forward 5’- 
TGGCAGAAAATGTCAGCAGC-3’ and reverse: 5’-GCAAAGGTAACCCTACTCGC-3’; targeted 
sequence in exon 12: forward: 5’-ACTCATAAGTTGCCAATCTAGT-3’ and reverse: 5’-
CTGGATGCTCACCAAGTATG-3’. 
 
Zebrafish imaging 
Differential interference contrast images of the inner ear and images of Alcian blue stained 
ceratohyal cartilages were acquired using a Zeiss Axioplan2 compound microscope. Images of 
immunolabeled cells and larvae were acquired using a Zeiss LSM 5 confocal microscope. Images 
were analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA). 
 
Statistical analysis 
For Golgi morphology count, a Chi-squared test was performed using R31 (script accessible in 
Supplemental Methods). For quantification of fibroblasts’ glycan peak intensities, multiple t-
tests were performed (one per row), with correction for multiple comparisons performed via 
the Holm-Sidak method, alpha=5.0%, using Prism 6.0c (Graphpad Software Inc, La Jolla, CA, 
USA). For other statistical analyses, an unpaired Student’s t-test was performed with Excel 
(Microsoft Corporation, Redmond, WA, USA). Statistical significance was assigned to a two-
tailed p-value <0.05.  
 
Results 
Clinical features 
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The clinical and imaging characteristics of fourteen individuals with SWS are summarized in 
Table 1. Individuals P2.1 and P12.1 were previously reported as two of the original probands 
with SWS (P12.1 corresponds to subject 2 in the original description of the syndrome by Saul 
and Wilson1, whereas P2.1 corresponds to subject 1 in Hersh et al.2). Affected newborns are 
born small for gestational age, have extreme short stature postnatally, and often have 
microcephaly, leading to a differential diagnosis within the microcephalic primordial dwarfism 
spectrum. Hearing loss appears to be another canonical feature of the disease. Representative 
clinical photos from subjects of different ages are shown in Figure 1, whereas characteristic 
radiographic findings are shown in Figure S1.  
 
A recurrent heterozygous variant in COG4 causes Saul-Wilson syndrome  
All subjects harbored one of two possible COG4 variants, c.1546G>A or c.1546G>C (GenBank: 
NM_015386.2). Both variants give rise to an identical de novo heterozygous amino acid 
substitution, p.Gly516Arg (NP_056201.2).  
 
Compared to control cells, fibroblasts from affected individuals showed normal mRNA 
expression (Figure 2A), and protein level of COG4 (Figure 2B) and other COG subunits (not 
shown) was not decreased, confirming that the variant leads to production of a stable protein. 
Protein modeling predicts the loss of a loop structure in the mutant protein (Figure S2). 
However, binding of COG4 to other COG subunits was not altered (Figure S3). 
 
Altered Golgi morphology and volume 
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Because the COG4 protein is part of a large COG complex that governs membrane movement 
between the Golgi and ER, we examined the morphology and total volume of the Golgi in 
fibroblasts obtained from individuals with SWS. Golgi morphology was significantly altered in 
fibroblasts of three tested subjects, with only 51.1% (n = 237, P1.1), 52.8% (n = 254, P4.1), and 
54.9% (n = 268, P5.1) of the Golgi complexes exhibiting normal morphology in contrast to 93.9% 
(n = 214, GM01582) in control fibroblasts (Figures 3A and 3B, Figure S4). Abnormal Golgi 
morphology was defined as co-localization of GM130 and TGN46, suggesting collapse of the cis- 
and trans-Golgi stacks. The Golgi volume in affected subject cells was significantly decreased 
compared to that of unaffected cells (p < 0.0001), since the volume in controls averaged 491 
μm3 based on staining with Giantin, a Golgi membrane marker; cells from affected individuals 
averaged 109 μm3 (Figure 3C). The nuclear volume was also decreased (1,158 μm3 in controls, 
729 μm3 in cells from affected subjects, p = 0.0016). After normalizing to nuclear volume, the 
volume of the Golgi in cells from affected individuals was 2.8-fold lower compared to that in 
control cells (p = 0.0005). 
 
Protein glycosylation occurs in the Golgi apparatus. Nevertheless, despite the marked reduction 
in Golgi volume within cells from subjects, glycan analysis in the mutant fibroblasts (Figure S5) 
and serum/plasma (Figure S6), as well as glycosylation status of serum transferrin and apoCIII 
(not shown), were not measurably different from that of controls.  
 
The initiation and polymerization of glycosaminoglycans onto its core protein (i.e., the 
glycosylation of proteoglycans) also takes place mainly in the Golgi apparatus. More than 98% 
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of decorin was secreted by fibroblasts to the extracellular matrix (data not shown). Extracellular 
decorin from affected individuals showed a greater proportion of higher molecular weight 
components compared to control cells (Figure 4A). Similarly, intracellular decorin in affected 
individuals exhibited a clear upward shift of the bands containing glycosaminoglycan (GAG) 
chains (Figure 4B). Finally, a smaller proportion of intracellular decorin contained extended GAG 
chains in affected individuals when compared to controls (Figure 4C). 
 
Brefeldin A-induced protein transport is impaired 
Brefeldin A (BFA) is an inhibitor of the vesicle membrane trafficking mediated by the coat 
protein complex, COPI. Such trafficking is involved in the process of Golgi-to-ER retrograde 
transport,32,33 in which the COG complex functions; hence BFA is widely used to examine the 
phenotype of human COG mutant cells. We treated control and affected subject fibroblasts 
with 0.25 µg/ml BFA at room temperature and recorded the increase in the ER-localized 
staining of Giantin over time. In previous studies using cells from individuals with biallelic 
variants in a single COG subunit, cells showed a delayed response to BFA treatment.14,22,24,34,35 
Surprisingly, the BFA-induced retrograde transport was significantly faster in affected subject 
cells compared to controls (Figure 5A). In contrast, when BFA was washed out and the Golgi 
allowed to reform, the anterograde transport was slower in cells from affected subjects 
compared to controls (Figure 5B).  
 
The trans-Golgi network (TGN) is a tubular-reticular structure adjacent to the trans-Golgi 
cisternae, acting as a protein sorting station with a role both in protein secretion and 
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endocytosis.36 BFA is known to produce effects in Golgi cisternae different from those in the 
TGN.37 In particular, BFA is known to alter the kinetics of recycling between the plasma 
membrane and the TGN.38 After BFA treatment, TGN46 was distributed in the cytoplasm as 
small, membrane-bound structures. Although the rate of loss of TGN structure was difficult to 
objectively quantify, this TGN breakdown appeared slightly faster in affected cells than in 
control cells; this difference was seen mainly 30 min after treatment (figure S7). 
 
The subcellular localization of COG subunits is unaltered 
Fractionation assays by differential centrifugation showed that the subcellular distribution of 
COG4 is unaltered. The majority of COG4 is in the cytosolic fraction (supernatant fraction from 
100,000g spin or 100kgS) and less than 5% of COG4 is membrane-bound (large membrane 
pellet fraction from 15,000g spin or 15kgP, and small membrane pellet fraction from 100,000g 
spin or 100kgP) in control and subjects’ cells (Figure S8). This is consistent with published data 
on COG4 distribution.24 The cytosolic vs membrane-bound distribution of the other COG 
subunits was also similar in control and affected subject cells (Figure S8).  
 
A portion of COG4 assembles into larger complexes 
The COG complex comprises eight subunits and their association and dissociation is dynamic. 
Density gradient centrifugation is a sensitive method to separate different-sized complexes 
formed by COG subunits.24 We observed the presence of two peaks of COG4 in the cytosolic 
fraction: the majority is present in fraction 4 in both control and subjects’ cells (Figure S9) but 
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there was a visible shift of approximately 13% of COG4 to heavier fractions in affected subject 
cells. The result indicates that a greater portion of COG4 exists in larger complexes.  
 
Zebrafish COG4-/- mutants have inner ear, growth and skeletal defects 
To establish the normal developmental functions of COG4, we used CRISPR/Cas9 gene editing 
to generate two mutant alleles of the zebrafish ortholog, cog4 (Figure S10). Both mutations 
introduced frameshifts followed by premature stop codons, one in exon 4 (cog4b1311, 
c.352_359del, p.I118Gfs*) and the other in exon 12 (cog4b1312, c.1499_1511del, p.D500Gfs*6). 
We did not observe significant differences in the phenotypes of the two alleles. As in affected 
subject’s fibroblasts, Golgi structure was disrupted in mutant cells (Figure S11), but unlike our 
observations from affected subjects’ fibroblasts (Figure S5) and serum/plasma (Figure S6), we 
found defects in the processing of N- and O-linked glycans (Figure S12A-B) and decreased 
glycosphingolipid complexity (Figure S12C). 
 
The inner ear was malformed in zebrafish mutants, with abnormally shaped semicircular canals 
(Figure 6A-B). Mechanosensory hair cells in the inner ear (Figure 6C-D, G) and neuromasts 
(Figure 6E-F, H) of mutants had reduced numbers of hair bundles. Response to auditory stimuli 
was greatly reduced in mutants (2% of 53 mutants responded, compared to 100% of 102 wild 
types). Homozygous mutant animals were significantly shorter than wild type ones (Figure 7A-
B, E; Z-score = -10.2). Mutants also had craniofacial defects (Figure 7A-D) with a smaller jaw, 
smaller inner ears (Figure 7A-B, F), slightly smaller eyes (Figure 7C-D), and stubby “clubbed” 
pectoral fins (Figure 7C-D). mRNA in situ hybridization showed that cog4 is expressed in these 
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structures (figure S13), and immunohistochemistry showed that the protein is deficient in 
biallelic mutants (Figure S14). Reduced Alcian blue staining of the jaw in mutants indicated 
defects in proteoglycan secretion (Figure 7G-H), and col1a2 expression was reduced in the fin 
(Figure 7I-J). Expression of collagen type II was normal in the jaw, however, suggesting that not 
all secreted proteins are affected by biallelic cog4 mutations. Notably, chondrocytes did not 
stack properly (Figure 7K-L). Taken together, these findings establish a role for cog4 in inner ear 
development and skeletogenesis, associated with defective Golgi structure. 
 
Discussion 
We show that a heterozygous de novo p.Gly516Arg COG4 variant is responsible for SWS, a rare 
skeletal dysplasia characterized by short stature, facial dysmorphisms, hearing loss, cataracts, 
developmental delay, and normal cognition. This is phenotypically distinct from the three 
reported individuals with classic, biallelic loss-of-function or hypomorphic COG4 mutations, 
who presented with seizures, hypotonia, intellectual disability, microcephaly, elevated 
transaminases and, in one case, recurrent infections,24,39–41 and from individuals with loss-of-
function mutations in other COG subunits associated with congenital disorders of glycosylation 
(CDG). These distinct phenotypes and the recurrent nature of the p.Gly516Arg variant therefore 
suggest the SWS mutation to be gain-of-function. Supporting this notion, SWS cells have 
accelerated, rather than the delayed retrograde Golgi-to-ER transport seen in cells with biallelic 
COG4 deficiency.24,40 In addition, loss-of-function COG4-mutant cells have impaired 
glycosylation and reduced COG4 protein levels,24 while SWS cells had no reduction in COG4 
protein level, with apparently normal glycosylation in serum, plasma and fibroblasts. 
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In SWS cells, accelerated retrograde transport combines with delayed anterograde transport to 
disrupt the normal dynamics of Golgi trafficking, creating smaller Golgi volumes. Despite the 
strikingly abnormal architecture of the Golgi and its collapsed stacks in almost 50% of 
fibroblasts from individuals with SWS, and the expected maldistribution of proteins toward the 
ER and away from the Golgi, glycosylation analysis in serum appeared normal, in contrast to the 
altered serum glycosylation seen in individuals with COG4-CDG. One caveat is that the 
expression of lobe B subunits was unaltered; prior studies have shown that lobe B is essential 
for preventing retrograde trafficking of β1,4-galactosyltransferase 1 and α2,6-sialyltransferase 
1.42 Additionally, glycomic analysis of the eleven most abundant fibroblast N-glycans did not 
detect statistically significant differences between control (n=2) and affected subject (n=5) cells. 
However, a comprehensive analysis of processing defects in affected subject cells would require 
the quantification of a significantly expanded portfolio of N-glycans in order to fully assess 
precursor/product flux through multiple, specific glycan biosynthetic pathways. The limited 
glycomic profiles we have quantified in control and affected subject fibroblasts are not 
sufficient to report whether altered Golgi morphology impacts any particular N-glycan 
processing pathway. Furthermore, efforts to understand the impact of the SWS COG4 variant 
on cellular glycosylation may benefit from assessing glycosylation in cell types other than 
fibroblasts that are more reliant on specific glycosylation pathways.  
 
Decorin is a widely-distributed extracellular matrix proteoglycan containing a single chondroitin 
sulfate (CS) or dermatan sulfate (DS) chain attached to serine residue 4.43 We found decorin 
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with a higher molecular weight both in media and inside fibroblasts from affected individuals. 
This could be due to longer glycosaminoglycan chain length, increased sulfation, or both. In 
addition, a smaller proportion of decorin is glycosylated with CS or DS. These results indicate 
that SWS affects at least two different aspects of decorin glycosylation, namely initiation, and 
polymerization or sulfation. Initiation of proteoglycan glycosylation takes place in early Golgi 
compartments (cis- and medial-Golgi), while polymerization and sulfation take place in late 
Golgi compartments (trans-Golgi and trans-Golgi network).44,45 This suggests that multiple Golgi 
compartments are affected in SWS cells. It has been previously shown that the biosynthesis of 
glycosaminoglycans depends on intact inter-compartmental Golgi transport,46 and that the COG 
complex is essential for normal intra-Golgi transport.24 Our zebrafish data support the fact that 
COG4 is necessary for normal secretion of proteoglycans (Figure 7G-H), and establish that it is 
required for normal skeletogenesis and cartilage architecture. 
 
Previous reports indicate that both COG4 deficiency and overexpression lead to disrupted 
vesicular homeostasis. Prior experiments have demonstrated that doubling expression of COG4 
protein in control cells via viral transduction led to abnormal retrograde trafficking,24 and 
lentiviral complementation of wild-type COG4 in fibroblasts derived from individuals with COG4 
deficiency failed to rescue the retrograde trafficking delay.40 In contrast, overexpression of the 
wild-type protein rescues the retrograde trafficking delay seen in fibroblasts of affected 
subjects with deficiencies of COG1,47 COG5,34 COG6,35 COG7,48 and COG822. Thus, this COG4 
dosage effect seems unique among COG complex proteins. A comprehensive investigation of 
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the impact of the SWS mutation on protein level and stability of COG4 and other lobe A 
subunits is currently being pursued.  
 
One consequence of the recurrent COG4 variant might be the formation of additional protein 
complexes. Human COG4 is known to interact with syntaxin 5, syntaxin 16, VTI1A, GOSR1, 
SCFD1, VPS45, RAB1A, RAB4A, RAB30, and VCP.10 Size distribution studies in affected subject 
cell extracts showed that COG4 protein was present in high molecular weight complexes, in 
keeping with the formation of intact COG complexes. Indeed, higher molecular weight 
complexes appeared to be more frequent in SWS cells, potentially suggesting the recruitment 
of additional interacting protein(s), which if confirmed may provide a useful avenue for future 
investigations. 
 
Whatever the cellular perturbations associated with the COG4 p.Gly516Arg variant, they result 
in the distinctive clinical phenotype of SWS, a skeletal dysplasia (Table 1). This is not the first 
example of a defect in vesicular trafficking altering skeletal homeostasis; other genetic defects 
cause variable phenotypes such as osteopetrosis49 (MIM: 611497 and 615085) with increased 
bone mineral density, a syndromic form of osteogenesis imperfecta50 (MIM: 616294) and 
geroderma osteodysplasticum51 (MIM: 231070) with bone fragility, rhizomelic short stature 
with deficiency of a subnit of the coatamer 1 protein complex52 (MIM: 617164), cranio-
lenticulo-sutural dysplasia (MIM: 607812) with abnormal anterograde vesicular trafficking,53 the 
lethal achondrogenesis type 1A54 (MIM: 200600), and Dyggve-Melchior-Clausen (MIM: 223800) 
with spondyloepimetaphyseal changes and delayed anterograde and retrograde trafficking.55 
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To that list, we now add a rare but likely underdiagnosed cause of primordial dwarfism, i.e., 
Saul-Wilson syndrome. 
 
Supplemental Data 
Supplemental Data include fourteen figures and Supplemental Methods, and can be found with 
this article online at http://www.cell.com/AJHG/home.  
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Table 1. Clinical, imaging and molecular features of individuals with Saul-Wilson syndrome. 
 P1.1 P2.1 P3.1 P4.1 P5.1 P5.2 P6.1 P7.1 P8.1 P9.1 P10.1 P11.1 P12.1 P13.1 
Gender M F M F M M M F M F M F M F 
Geographic origin Am Am Ger Brz Am Am Am Am Swe Can Dan Hisp Am Kor 
Age at last 
examination 
4y 4m 29y 6y 9m 7y 4m 8y 0m 3y 
10m 
9y 0m 27y 9m 9y 10y 
8m 
18m 39y 3y 2m 
Growth parameters 
Birth weight in kg 
(Z-scorea) 
2.2     
(-2.2) 
2.52   
(-1.7) 
1.85   
(-2.7) 
1.45 (-
3.8) 
2.24    
(-2.1) 
1.75   
(-2.9) 
2.18    
(-2.2) 
1.96    
(-2.8) 
2.8      
(-1.2) 
2.13   
(-2.5) 
2.78    
(-1.3) 
1.81    
(-3.1) 
1.5     
(-3.3) 
2.15    
(-2.4) 
Birth length in cm 
(Z-scorea) 
43.1    
(-2.6) 
48      
(-0.7) 
44      
(-2.3) 
38 (-
5.1) 
48.3   
(-0.7) 
41      
(-3.4) 
45.5   
(-1.7) 
ND 46       
(-1.6) 
39      
(-4.7) 
49      
(-0.4) 
42       
(-3.3) 
ND 45       
(-2.0) 
Birth OFC in cm (Z-
scorea) 
32.7   
(-1.4) 
32      
(-1.9) 
30      
(-2.6) 
29 (-
3.9) 
33      
(-1.3) 
31.5    
(-1.9) 
30.5   
(-2.4) 
ND 33.5    
(-1.1) 
30.5     
(-2.9) 
34       
(-0.8) 
ND ND 32      
(-1.9) 
Current weight in 
kg (Z-scorea) 
9.7     
(-4.2) 
25.3   
(-4.8)  
9.8     
(-5.0) 
9.5 (-
4.9) 
14.5    
(-3.7) 
9.25   
(-4.3) 
21.3   
(-2.0) 
27.2   
(-4.5) 
5.76    
(-3.8) 
24.6   
(-1.1) 
16       
(-3.9)  
5.15    
(-5.8) 
39       
(-3.6) 
7.7      
(-4.6) 
Current height in 
cm (Z-scorea) 
80.9   
(-5.4) 
109.7 
(-8.3) 
86.2    
(-6.4) 
82 (-
7.7) 
93.4   
(-6.0) 
78      
(-5.6) 
107    
(-4.3) 
107.1 
(-8.7) 
62.5    
(-3.5) 
109    
(-4.0) 
105     
(-5.4) 
59.5    
(-6.3) 
106     
(-9.8) 
71       
(-6.2) 
Current OFC in cm 
(Z-scorea) 
48.4   
(-1.5) 
49      
(-5.0) 
46.5   
(-4.0)  
48.5 (-
2.4) 
50.6   
(-1.2) 
51.2 
(+0.6) 
50      
(-1.9) 
51.4   
(-2.7) 
46.2 
(+0.8) 
51      
(-0.7) 
51      
(-1.5) 
43.5    
(-2.6) 
ND 48.5    
(-0.2) 
Craniofacial features 
Progeroid 
appearance 
+ + + + - - + - - + + + - - 
Prominent 
forehead 
+ + + + + + + + + + + + + + 
AF enlargement or 
closure delay 
+ + + + ND +  + ND + + + + + + 
Narrow nasal 
bridge 
+ + - + + - + - - - + + + - 
Convex nasal ridge  - + + + - - + - - - - + + - 
Micrognathia + + + + - - + + + + + + + + 
Prominent veins + + + + visible visible + visible + + + + + + 
Ophthalmic features 
Blue sclerae + + - + - - - + - - + + + + 
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Prominent eyes + + + + + + + + + + + + + - 
Cataracts + + + + + - + + - + + ND + - 
Retinal 
involvementb 
+ + - + - ND ND + ND + + 
 
ND ND - 
Audiologic features 
Hearing loss BL 
SNHLc 
BL 
SNHL 
-  BL  
mixed  
BL 
cond 
Cond BL 
cond 
+ - -  + + + BL 
cond 
Hematologic features 
Neutropenia - - + + + ND + ND - - + + + + 
Development 
Speech delay + + + +  ND ND + ND ND - - + + - 
Motor delay + + + - + + - ND +  - + + + + 
Skeletal features 
Pectus  + + - + - - - + - - - - + - 
Clubfoot + + - + + - + - + - + + + + 
Short distal ph + + + + + + + + - + + - + + 
Radiographic features 
Overtubulation of 
long bones 
+ + + + + + + + + + + ND + + 
Metaphyseal long 
bone flaring 
+ + + + 
(mild) 
+ 
(mild) 
+ + + + + + ND + + 
Megaepiphyses + + + +  +  + + + + + + ND + + 
Coxa valga + + +  + + + + + + + + ND + + 
Dysplastic proximal 
radius 
+ + + + + + + ND + - + ND ND + 
Madelung-like 
deformity of wrist 
- + - +d +d - - ND - + - ND - - 
Shortening of 
proximal fibula 
+ + + 
(mild) 
- + 
(mild) 
+ + ND + - + ND ND + 
Premature DJD -e + -e -e -e -e -e + -e -e -e ND + -e 
Platyspondyly + +f - +f +f - - ND +  - + ND - + 
Irregular vertebral 
endplates  
+ 
(mild) 
+ - +g +g - + ND + 
(mild) 
+ 
(mild) 
+ ND + + 
(mild) 
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Hypoplasia of T12 
or L1 
- + - + + + + + - - - ND + - 
Dens hypoplasia  + + + + + + + + + + + ND + + 
Subluxed C1-C2  - - +  - - - - + - - + ND - - 
Platybasia + + ND + + + + ND - + + ND ND - 
Short mt/mc/ph  + + + + + + + ND + + + ND + + 
Cone-shaped 
epiphyses of ph 
+ + + + + + + ND +  + + ND + + 
Ivory epiphyses of 
ph 
+ + - + + -e + ND -e + + ND + -e 
Pseudoepiphyses 
of mc 
+ + + + + + + ND -e + + ND + + 
Neuroimaging features 
Ventriculomegaly +  ND - - +h ND +  ND ND - +  +  ND - 
SC compression + + - + - ND ND ND ND - - ND ND ND 
SC syrinx ND + ND - ND ND ND ND ND - - ND ND ND 
Molecular findings 
cDNA change 
(NM_015386.2) 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>C 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>A 
c.1546
G>C 
c.1546
G>C 
Protein change 
(NP_056201.2) 
p.Gly516Arg 
 
Abbreviations: AF, anterior fontanelle; Am, American; BL, bilateral; Brz, Brazilian; Can, Canadian; cond, conductive; Dan, Danish; DJD, 
degenerative joint disease; F, female; Ger, German; Hisp, Hispanic; IAC, internal auditory canal; Kor, Korean; M, male; mc, 
metacarpals; mt, metatarsals; ND, not described; HL, hearing loss; OFC, occipitofrontal circumference; ph, phalanges; SC, spinal cord; 
SNHL, sensorineural hearing loss; Swe, Swedish. 
a Z-scores calculated using 2000 Centers for Disease Control and Prevention (CDC) growth charts.b Retinal pigmentary changes or 
night blindness. c Failed newborn hearing screen; temporal bone CT at 4 months of age showed dysplastic cochlea, dilated and 
bulbous internal auditory canals, and mildly dilated vestibules and semicircular canals. d Mild; manifests with age. e Too young to 
assess. f At younger age; become tall vertebrae with age. g At older age. h Hydrocephalus.  
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Figure titles and legends 
Figure 1. Clinical features of individuals with Saul-Wilson syndrome 
(A) P2.1 as an infant, showing a progeroid appearance, sparse eyebrows, and thin vermillion of 
the upper lip. (B) P8.1 at 6 months of age, showing prominent forehead, veins, and eyes, thin 
vermilion of the upper lip, and micrognathia. (C) P6.1 at 7 months of age, showing a progeroid 
appearance, relative macrocephaly, prominent forehead and veins, sparse eyebrows, low-set 
ears, low hanging columella, thin vermillion of the upper lip, and use of boots and bar orthosis 
as therapy for clubfoot. (D) P10.1 at 7 months of age, showing prominent scalp veins and low-
set ears. (E) P4.1 at 1 year of age, showing relative macrocephaly, prominent forehead, veins 
and eyes, sparse eyebrows, low hanging columella, and thin vermillion of the upper and lower 
lips. (F) P3.1 at 14 months of age, showing prominent forehead, veins, and eyes, and thin 
vermillion of the upper and lower lips. (G) P7.1 at 20 years of age, showing prominent forehead, 
sparse eyebrows, narrow nasal bridge, low hanging columella, and thin vermillion of the upper 
lip. (H) P2.1 at 29 years of age, showing prominent forehead, sparse eyebrows, narrow nasal 
bridge, low hanging columella, and thin vermillion of the upper and lower lips. (I) P2.1 at 29 
years of age, showing telebrachydactyly. 
 
Figure 2. COG subunit expression 
(A) mRNA expression of each of the COG-subunits in P1.1 (gray) compared to control 
(GM08398, black). No significant changes in expression were observed. Measurements were 
performed in quadruplicate. Error bars represent 95% confidence interval. (B) Infrared 
fluorescent Western blot analysis (left) of COG4 in three control (GM08398, GM01582 and 
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ATCC63792061) and three affected subject (P1.1, P4.1 and P5.1) fibroblast lines. Vinculin served 
as a loading control and in the calculation of normalized signal intensity. Densitometric analysis 
showing normalized signal intensity of COG4 in individual samples (middle). Mean protein level 
of COG4 in affected subjects vs controls; error bars represent standard deviation.  
 
Figure 3. Golgi morphology and volumetric analysis 
(A) Compared to control fibroblasts (GM01582) that had normal Golgi morphology in 93.9% of 
the cells, P1.1, P4.1, and P5.1 only had normal morphology in 51.1%, 52.8%, and 54.9% of their 
cells, respectively. ∗∗∗p < 0.0005 compared to the control. Affected subjects did not 
significantly differ from each other. (B) Representative images of a Golgi with normal 
morphology in the control fibroblasts and a Golgi with abnormal morphology in P1.1 
fibroblasts. Images were taken using the 63× oil-based objective. Cis-Golgi is stained with 
GM130 (red), trans-Golgi with TGN46 (green), and DNA with Hoescht 33342 (blue). The yellow 
signal in the affected subject cells represents co-localization of GM130 and TGN46, suggesting 
that the cis- and trans-Golgi are collapsed. (C) The volumes of Giantin-labeled Golgi and DAPI-
labeled nuclei were determined by Imaris software. A significant decrease in the ratio of Golgi-
to-nucleus volume was seen in affected subject cell lines. Controls represent the average ratio 
for five cells from ATCC63792061 and GM8398 cell lines. Affected subjects represent the 
average ratio for 13 cells from P1.1, P4.1 and P5.1 cell lines. Error bars represent SD. ∗∗p < 
0.005. 
 
Figure 4. Decorin immunoblotting in control and affected individual fibroblasts   
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(A) Western blot analysis of secreted decorin. (B) Western blot analysis of intracellular decorin. 
The size ranges for the fully glycanated form of decorin and its core protein are indicated. A 
portion of decorin is extended with glycosaminoglycan chains (MW 100-130+kD), while a 
significant portion is not glycosylated and runs as a doublet at about 40kD. (C) Levels of 
glycanated decorin were quantified against total decorin levels. Experiments were repeated in 
duplicate with similar results. Representative blots are shown. **, p<0.005.  
 
Figure 5. Brefeldin A trafficking assays 
(A) BFA-induced retrograde transport kinetics of control and affected subject cells. Between 80 
and 100 cells were counted for each time point. The experiment was performed in duplicate. 
C1, ATCC63792061; C2, GM08398. (B) Golgi protein anterograde transport kinetics of control 
and affected subject cells was measured after treatment with BFA for one hour followed by 
washout (T=0). Between 80 and 100 cells were counted for each time point. The experiment 
was performed in duplicate. C1, ATCC63792061; C2, GM08398; COG8, positive control. Error 
bars represent standard deviation.  
 
Figure 6. Morphogenesis and function of the inner ear are abnormal in cog4-deficient 
zebrafish  
(A-B) Morphology of the inner ear in cog4 sibling (A) and cog4-/- mutant (B) larvae. Red stars 
indicate the semicircular canals. (C-F) Phalloidin staining of the anterior macula in cog4 sibling 
(C) and cog4 mutant (D) larvae. Phalloidin staining of the second posterior neuromast in cog4 
sibling (E) and cog4 mutant (F) larvae. (G) Number of hair bundles in the anterior macula of 
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cog4 mutants (n=15 larvae) and cog4 siblings (n=14 larvae). (H) Number of hair bundles in the 
second posterior neuromast of cog4 mutants (n=6 larvae) and cog4 siblings (n=7 larvae). ** 
p<0.01. All data obtained at 5 dpf, anterior to the left (A-F). 
 
Figure 7. Zebrafish cog4-deficient mutants have morphological and secretory defects  
(A-B) Lateral views of (A) cog4 sibling and (B) biallelic cog4-/- mutant larvae. Red dashed lines 
indicate the anterior (jaw extension) and posterior (caudal fin) ends of the wild-type larvae. Red 
double arrow in B marks the length difference between wild-type and mutant larvae. Blue 
arrowheads indicate the inner ear. (C-D) Dorsal views of cog4 sibling (C) and cog4-/- mutant (D) 
larvae. Orange arrowheads indicate the eyes, and purple arrowheads the pectoral fins; green 
arrowhead indicates the forward extent of the jaw in (C). (E) Body length in homozygous wild-
type cog4+/+ (n=7 larvae), heterozygous cog4+/- (n=37 larvae) and biallelic homozygous cog4-/- 
mutant larvae (n=17 larvae). Length was measured as in A. (F) Inner ear size in cog4+/+ (n=14), 
cog4+/- (n=70), and cog4-/- larvae (n=21). Size was measured as distance along the antero-
posterior axis of the inner ear. ** p<0.01. (G-H) Alcian blue staining of the ceratohyal in cog4 
sibling (G) and biallelic mutant (H) larvae. (I-J) col1a2 mRNA in situ hybridization in the pectoral 
fin of cog4 sibling (I) and mutant (J) larvae. (K-L) Immunolabeling of Collagen type II in the 
ceratohyal of cog4 sibling (K) and mutant (L) larvae. All data obtained at 5 days postfertilization 
(dpf), anterior to the left (A-D, G-L). 
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